---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-085887"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:27:12.552563+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Organon Q2 revenues $1.585B (-1% as-reported, +5% ex-FX); adj EPS $1.25; FY guidance narrowed

## Summary
- Q2 revenues $1,585M, down 1% as-reported but up 5% ex-FX vs Q2 2021; diluted EPS $0.92, adj diluted EPS $1.25 (both include -$0.30 IPR&D).
- Adjusted EBITDA $512M (32.3% margin), inclusive of $97M acquired IPR&D and milestones.
- Board declares quarterly dividend $0.28/share (unchanged).
- Full-year 2022 revenue guidance narrowed to $6.1B-$6.3B; adj EBITDA margin 32%-34% reflecting FX and IPR&D.
- Biosimilars revenue +42% ex-FX; Established Brands +4% ex-FX; Women's Health +1% ex-FX.

## SEC filing metadata
- accession: 0001104659-22-085887
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465922085887/0001104659-22-085887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465922085887/tm2222382d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-085887
- JSON: https://secwatch.observer/filing/0001104659-22-085887.json
- Plain text: https://secwatch.observer/filing/0001104659-22-085887.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.